

Ortho, Brahms agreement, 9/17

September 2017—Ortho Clinical Diagnostics announced a strategic relationship with Brahms GmbH, part of Thermo Fisher Scientific, to develop the Brahms PCT assay for use on Ortho's Vitros Systems. The Brahms PCT assay is used in conjunction with other laboratory findings and clinical assessment to aid in sepsis management, including early identification of patients at higher risk of progressing to septic shock, identifying when it is safe to discontinue antibiotics, and establishing mortality risk in septic patients. The assay also plays a role in antibiotic stewardship, aiding physicians in decision-making for lower respiratory tract infections. Ortho is currently developing the assay for use on the company's Vitros Immunodiagnosics and Integrated Systems for small-, mid-, and high-volume clinical labs.

The company also announced that Ortho's Vitros Immunodiagnostic Products Insulin Reagent and Calibrators have received FDA 510(k) clearance and the CE mark. An important biomarker in diabetes and prediabetes testing, the assay is expected to be commercially available for use on all of Ortho's Vitros Immunodiagnostic and Integrated Systems in the U.S., Europe, and other countries accepting the CE mark during the third quarter of this year.

[***Ortho Clinical Diagnostics***](#), 800-828-6316